Kandungan kolesterol yang berlebihan dalam tubuh akan mengganggu kesehatandengan munculnya berbagai penyakit komplikasi serius seperti penyakit jantungatau stroke. Obat golongan statin, seperti simvastatin, dapat menurunkankonsentrasi kolesterol dalam tubuh. Simvastatin berfungsi untuk menghambataktivitas enzim HMG-CoA reduktase. Waktu paruh simvastatin sekitar 2-3 jam,sementara bioavailabilitas oral simvastatin hanya 5% sehingga konsumsi obatsimvastatin harus dilakukan secara berulang. Hal ini menyebabkan fluktuasikonsentrasi obat dalam tubuh karena terdapat dua kondisi ketika obat tidaksepenuhnya diserap oleh tubuh atau ketika obat sepenuhnya diserap oleh tubuhsehingga konsentrasinya terlalu tinggi. Hal ini menimbulkan efek samping sepertikerusakan hati, miopati, dan anemia. Untuk mengatasi hal itu, dibutuhkan sistempenghantaran obat terkendali (CDDS). Pada penelitian ini, teknik mikroenkapsulasisimvastatin digunakan untuk mengendalikan laju disolusi obat. Mikroenkapsulasisimvastatin dilakukan menggunakan penyalut berbahan polipaduan poli(D,L-asamlaktat) (PDLLA) dan polikaprolakton (PCL) dengan komposisi 1:9 dan poli(etilenaglikol) (PEG) sebagai agen pembuka pori dan membentuk morfologi spherisdengan rata-rata ukuran mikrokapsul mencapai 0,538 μm. Untuk mendapatkankondisi optimum penjerapan obat, dilakukan variasi berat molekul 400, 4000, dan35000 g/mol PEG serta variasi massa PEG mulai dari 0%, 5%, 10% dan 15%(%wt). Surfaktan yang digunakan adalah Tween 80 dan Span 80 melalui metodeevaporasi pelarut (o/w). Kondisi optimum diperoleh pada penggunaan PEG 400g/mol 15 %wt dengan persen efisiensi enkapsulasi simvastatin sebesar 92,06 % danpersen pelepasan obat sebesar 29,94%. Setiap gram mikrokapsul yang terbentukmengandung 76,78 mg simvastatin dengan potensi pelepasan obat sebanyak 23 mg.

---

The high amount of cholesterol can affect our health with the emergence of various

complications such as heart disease or stroke. A statin class drug, such as

simvastatin is needed to overcome this problem by decreasing cholesterol levels

with an excessive amount. Simvastatin itself has a function to inhibit the activity of

the HMG-CoA reductase enzyme. The half-life of simvastatin is around 2-3 hours,

while the oral bioavailability of simvastatin is only 5%, so the consumption of

simvastatin should be repeated. This causes fluctuations of drug concentration in

the body because there are two conditions when the drug is not fully absorbed by

the body or when the drug is fully absorbed by the body so that the concentration is

too high. This causes side effects such as liver damage, myopathy, and anemia. A

controlled drug delivery system (CDDS) is needed to overcome this. The

simvastatin microencapsulation technique was applied to control the dissolution

rate of the drug. Simvastatin microencapsulation was carried out using a coating

made from a combination of poly (D, L-lactic acid) (PDLLA) and polycaprolactone

(PCL) with a composition of 1:9 and poly (ethylene glycol) (PEG) as a pore opening

agent and forming a spherical morphology with the average size of the

microcapsules reached 0.538 μm. To obtain the optimum conditions for drug

absorption, various molecular weights of 400, 4000, and 35000 g/mol of PEG were

carried out as well as variations in PEG mass ranging from 0%, 5%, 10% and 15%

(%wt). The surfactants used were Tween 80 and Span 80 by the solvent evaporation

(o/w) method. The optimum conditions were obtained when using PEG 400 g/mol

15% wt with a percent efficiency of simvastatin encapsulation of 92.06 % and a

percentage of drug release of 29.94%. Each gram of microcapsules formed contains

76.78 mg of simvastatin with a drug release potential of 23 mg.